Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns. Zhang Y, Dai X, Liang J, Yang C, et al. Lung Cancer 2025;207:108715.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhang Y, Dai X, Liang J, Yang C, et al. Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns. Lung Cancer 2025;207:108715.
PMID: 40818197